ClinicalTrials.gg
Not yet recruitingNCT07372859COEURUpdated Oct 9, 2026

Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners

An interventional study of Echocardiography and Arterial ultrasound in Healthy Volunteer, sponsored by French Cardiology Society. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by French Cardiology Society · Not applicable, Interventional, and Other

How we know

Updated Oct 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to describe the cardiac and systemic inflammatory adaptations specific to women practicing ultra-endurance sports.

The objectives are to:

  • Improve the understanding of cardiac and systemic inflammatory adaptations specific to women participating in ultra-endurance sports.
  • Assess the relationship between observed cardiac and systemic inflammatory alterations and the relative levels of estrogen, testosterone, and progesterone.
  • Describe the vascular adaptations specific to women participating in ultra-endurance sports.
  • Examine the influence of defense mechanisms on the emotional dynamics observed during and after an ultra-endurance race.
Read the detailed description

This is a French national non-comparative descriptive study. The study is conducted on healthy volunteers. 80 to 100 patients will be included, half of the inclusions on the "Ecotrail de Paris Ile France©"( = a trail running race in the Paris region. It is not possible to translate; it is a registered trademark) the second half of the inclusions on the "6000D©" in Savoie.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • ultra endurance
03

In context

Lead sponsor

French Cardiology Society is the lead sponsor of 85 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a Global Positioning System watch during the race;
  • Must participate in one of the following races:

    • "Ecotrail de Paris Ile France©" (=a trail running race in the Paris region, it is not possible to translate; it is a registered trademark) 80 kilometers;
    • Or "la 6000D©" 69 kilometers;
  • Must comply with the race regulations:

    • Medical certificate stating no to competitive running, dated less than 12 months prior to the race;
    • Or a valid sports license on the day of the race.
  • Must agree to participate in the study, sign the consent form, and allow the sponsor to use their data for the purposes of this study.

Exclusion criteria

Exclusion Criteria:

  • Refusal or linguistic or mental incapacity to sign the form;
  • Person under guardianship (conservatorship, curators, or legal protection) or deprived of liberty;
  • Person not affiliated with a social security scheme;
  • Pregnant woman;
  • Person participating in a drug study;
  • Women with a medical history (chronic lung disease, heart disease, pharmacologically treated hypertension) or with a known significant chronic inflammatory disease at the time of the enrollment visit;
  • Person who has already participated in this study in a previous race.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants will undergo examination before the race, during the race, at the arrival of the race, and 9 days after the race.

    Procedure: Echocardiography · Procedure: Arterial ultrasound · Biological: Blood sampling · Behavioral: Scales and questionnaire · Procedure: Vital signs · Biological: Urinary test

Interventions

  • ProcedureEchocardiography

    6 transthoracic echocardiography will be performed: 1 before the race, 3 during the race (refreshment station), 1 at the end of the race, 1 at the follow up visit 9 days after the race. It is not possible to specify the intervention time, as this depends on the participants' running pace.

  • ProcedureArterial ultrasound

    6 ultrasound of the carotid and femoral arteries will be performed: 1 before the race, 3 during the race (refreshment station), 1 at the end of the race, 1 at the follow up visit 9 days after the race. It is not possible to specify the intervention time, as this depends on the participants' running pace.

  • BiologicalBlood sampling

    6 blood sampling (2 milliliters) will be performed: 1 before the race, 3 during the race (refreshment station), 1 at the end of the race, 1 at the follow up visit 9 days after the race. It is not possible to specify the intervention time, as this depends on the participants' running pace.

  • BehavioralScales and questionnaire

    Before the race, during the race (refreshment station), and at the end of the race participant will be asked to complete the study questionnaire and scales. It is not possible to specify the intervention time, as this depends on the participants' running pace.

  • ProcedureVital signs

    6 measurements of blood pressure, heart rate, respiratory rate, pulse oxygen saturation, and muscle oxygen saturation will then be taken: 1 before the race, 3 during the race (refreshment station), 1 at the end of the race, 1 at the follow up visit 9 days after the race. It is not possible to specify the intervention time, as this depends on the participants' running pace.

  • BiologicalUrinary test

    Pregnancy test will be performed before the race.

06

What researchers measure

Primary outcomes

  1. Cardiac function

    Echocardiographic measurements of left ventricular ejection fraction as a percentage

    Time frame: Before the race, at the 3 refreshment stations, at the arrival of the race, 9 days after the race.

  2. Systemic inflammatory parameters

    Inflammatory profile adjusted for baseline

    Time frame: Before the race, at the 3 refreshment stations, at the arrival of the race, 9 days after the race.

Secondary outcomes

  1. Hormonal parameters

    Hormonal profile adjusted for baseline

    Time frame: Before the race, at the 3 refreshment stations, at the arrival of the race, 9 days after the race.

  2. Vascular adaptations

    Carotid artery and femoral artery diameter adjusted for baseline

    Time frame: Before the race, at the 3 refreshment stations, at the arrival of the race, 9 days after the race.

  3. Defense mechanisms regarding emotional dynamics

    Defense Style Questionnaire-26 questionnaire is a standardized questionnaire developed to assess defense mechanisms: adaptive (humor, anticipation, self-assertion, altruism, self-observation) and maladaptive defenses (help rejecting complaining, splitting other, projection, dissociation, intellectualization, devaluation/self, fantasy, devaluation of other). These items are rated on a Likert scale from 1 to 6 points; 1 corresponding to "strongly disagree" and 6 to "strongly agree".

    Time frame: Before the race, at the 3 refreshment stations, at the arrival of the race.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Mar 2027; primary completion for Sep 2027, 6 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Mar 2026 → Mar 2027, primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 28, 2026
StartEst.
Mar 20, 2027was Mar 2026
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 22, 2026→Mar 20, 2027
Oct 9, 2026
Primary completion
Sep 30, 2026→Sep 30, 2027
Oct 9, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Mar 22, 2026→Mar 20, 2027
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07372859
Lead sponsor
French Cardiology Society
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Mar 20, 2027 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Tessa BERGOT, MSc
Contact
tessa.bergot@sfcariod.fr
+33144907033
Romain JOUFFROY, MD
principal investigator · CHU d'Orléans

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion